The only prior computational study that proposed that our top-ranked drug candidate dolutegravir may inhibit SARS-CoV-2 helicase, involved a deep learning model . This study suggested that dolutegravir also inhibits several other viral targets. Indu et al. also used MD studies and Autodock Vina to identify dolutegravir as a potential inhibitor of SARS-CoV-2 M pro and RdRp . If these activities of dolutegravir are subsequently confirmed, its ability to hit several viral targets simultaneously may make it particularly effective for treating COVID-19 patients. For example, such multitarget drug approaches have been very effective in controlling HIV infections.